|
Praveen Tyle, Ph. D. is Bausch & Lomb senior vice president - Research and Development and Chief Scientific Officer, responsible for the Company's research, new product development, preclinical development, project management,clinical, medical and regulatory affairs, and product quality.
Dr. Tyle joined Bausch & Lomb in July 2004 from Biovail where he was group vice president - pharmaceutical sciences and manufacturing. Prior to that, he was vice president and global head - pharmaceutical sciences at Pharmacia Corporation.
Dr. Tyle has 23 years of drug development and commercialization experience. He began his professional career as a formulations research chemist in drug delivery research with American Cynamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). In 1999, Dr. Tyle was named vice president - pharmaceutical sciences, U.S., Pharmacia & Upjohn (now Pfizer).
Dr. Tyle holds academic appointments as an adjunct professor of Ophthalmology at the University of Rochester Eye Institute, as well as an adjunct professor of Pharmacy at the University of Rhode Island, at the Howard University, Washington DC, and at the University of Houston, Texas. He is editor of seven books about drug development, holds several patents and is the author of more than 125 technical and scientific papers and presentations.
Dr. Tyle was born in Hapur, India, in March 1960. He holds a doctorate in Pharmaceutics and Pharmaceutical Chemistry from Ohio State University (1984) and a bachelor of Pharmacy degree from the Institute of Technology, Banaras Hindu University, India. (1980). Dr. Tyle is a member of the Board of Directors for Orient Europharma Ltd., Taiwan and Scientific Advisory Board member of VioQuest Pharmaceuticals, Inc., New Jersey. | 